Pfizer Inc. $PFE Stock Holdings Reduced by Townsquare Capital LLC

Townsquare Capital LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 35.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 132,599 shares of the biopharmaceutical company’s stock after selling 72,177 shares during the quarter. Townsquare Capital LLC’s holdings in Pfizer were worth $3,302,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Pfizer by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. State Street Corp grew its stake in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares in the last quarter. Geode Capital Management LLC grew its stake in Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Norges Bank purchased a new position in Pfizer in the fourth quarter valued at about $1,830,986,000. Finally, Northern Trust Corp raised its holdings in shares of Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after purchasing an additional 869,175 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: RBC Capital Markets upgraded Pfizer to Sector Perform from Underperform, saying recent declines have reset valuation and reduced downside risk ahead of upcoming pipeline catalysts. Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
• Positive Sentiment: Pfizer received FDA support for an expanded use of HYMPAVZI in pediatric hemophilia patients, which strengthens the company’s rare disease growth narrative and broadens the drug’s commercial opportunity. PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
• Positive Sentiment: Pfizer also highlighted progress in its pipeline with updates on a next-generation pneumococcal shot and its mid-stage obesity program, reinforcing investor attention on future growth drivers beyond its legacy products. Pfizer’s Next-Gen Pneumococcal Shot: What a Fresh Trial Update Means for PFE Investors
• Positive Sentiment: Pfizer’s expanding obesity pipeline remains a potential long-term catalyst, as investors continue to look for a meaningful comeback story after the post-COVID revenue reset. Will obesity drugs save Pfizer from its post-COVID slump?
• Neutral Sentiment: Healthcare stocks overall fell late Wednesday, which likely added sector-level pressure on Pfizer even as company-specific news remained constructive. Sector Update: Healthcare Stocks Decline Late Afternoon
• Neutral Sentiment: Pfizer CEO Albert Bourla warned that German investment could be slowed or resized if drug-pricing proposals reduce returns, a reminder that pricing policy risk remains a headwind for the business. Pfizer CEO warns German investment at risk over drug pricing policies

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Barclays assumed coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research note on Thursday, February 12th. Finally, Guggenheim upped their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer Stock Down 0.4%

PFE stock opened at $25.61 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a 50-day moving average of $26.52 and a two-hundred day moving average of $26.32. The stock has a market capitalization of $145.93 billion, a price-to-earnings ratio of 19.55 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the company earned $0.92 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio is presently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.